anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Aspects of the invention include a computer-implemented method including extracting a domain-specific object feature from a first image data, wherein the feature describes an object in the first image data. A domain-specific semantic meaning of text data is determined. The object feature is mapped to a portion of the text data, wherein the portion of the text data describes the object. A joint representation of the object and the portion of the text data is created. A second image data and a query directed towards an object in the second image data is received. An answer to the query is generated based on the joint representation.
PURPOSE: A composition and a health functional food containing a Caryophylli cortex extract are provided to induce pancreatic cancer apoptosis and to effectively prevent and treat pancreatic cancer. CONSTITUTION: A composition and a health functional food for treating pancreatic cancer contain a Caryophylli cortex extract which is prepared using an organic solvent at 50 deg. C. for 24 hours. The organic solvent is ethanol. The extract is dried and concentrated at 45 deg. C. The composition contains a pharmaceutically acceptable carrier or diluents. The pancreatic cancer is pancreatic ductal adenocarcinoma. [Reference numerals] (AA) Relative cellular viability
BACKGROUND: The World Health Organization (WHO) cautions against unnecessary prolongation of postoperative antibiotics to prevent surgical site infections (SSI), however this practice is still common in many countries. This study aims to describe drivers of prolonged postoperative antibiotic prescribing and clinicians' perspectives on antibiotics resistance and stewardship in Ethiopia.
METHODS: We conducted semi-structured interviews of 16 surgeons and nine surgical ward nurses at three academic referral hospitals in Addis Ababa. Audio recordings were transcribed verbatim and coded. Codes were inductively and iteratively derived between two researchers, tested for inter-rater reliability (IRR), and the codebook was consistently applied to all transcripts. Thematic analysis was performed to understand drivers of prolonged prophylactic antibiotic use in surgical patients.
RESULTS: Interviews revealed factors contributing to postoperative prophylactic antibiotics overprescribing, including inadequate infection prevention and control (IPC) practices, wide variability in local prescribing practices, and distrust in the applicability of WHO guidelines. Antimicrobial resistance was also identified as a major concern by staff. Barriers to improving stewardship included a lack of multidisciplinary teamwork to inform prescribing decisions, while solutions included constructing appropriate context-specific guidelines and improving evidence-based practices through input from local stakeholders, including surgeons, clinical pharmacists, and nurses.
CONCLUSIONS: Study participants perceived that existing evidence and guidelines did not apply in their settings due to high rates of surgical site infections and gaps in perioperative IPC practices (e.g., availability of water for handwashing, sterility breaches). These gaps were a key contributor to prophylactic antibiotic overprescribing, reinforcing the need to strengthen upstream and perioperative surgical antisepsis processes. The findings of this study underscore the importance of engaging multidisciplinary teams in strengthening antimicrobial stewardship efforts, aligning processes to achieve compliance with best practices, and the need for rigorous, contextually appropriate studies from these settings to inform policy.
PURPOSE: Meniscal wrapping is a fully arthroscopic technique that involves enhanced meniscal repair with a tissue-engineered collagen matrix wrapping. This study aims to investigate the feasibility of using the meniscal wrapping technique for the treatment of chronic or complex meniscal tears. The primary objective is to assess its failure rate. The secondary objectives are to analyse complication rate, functional outcomes and overall patient satisfaction.
METHODS: This retrospective case series study included patients who sustained chronic and complex tears undergoing meniscal wrapping with autologous liquid bone marrow injection. Failure rate was considered if the patient underwent partial or complete meniscectomy or knee replacement during the follow-up, while other unexpected knee reoperations were considered as complications. Clinical outcomes were evaluated through the IKDC score, Tegner Activity Score and Short Assessment of Patient Satisfaction.
RESULTS: Twenty-one patients were included (15 non-acute bucket-handle tears, three non-acute horizontal tears and three non-acute complex injuries). The failure rate was 9.5% at 33 months. The rate of other unplanned reoperations was 14.3%, but none of these complications were apparently directly related to the wrapping technique. The average postoperative IKDC was 73.3/100. No statistically significant difference was encountered between preinjury and postoperative Tegner Activity Score. The mean overall patient satisfaction was 88.3/100.
CONCLUSIONS: Meniscal wrapping can be safely used as an adjunctive technique to meniscal repair in such difficult-to-treat cases to preserve the meniscus. The technique achieves a low failure rate and promising results of knee function, and patient satisfaction.
The invention relates to a tumor targeting protein or a fragment thereof, an antibody combined with the tumor targeting protein and application of the tumor targeting protein and the fragment. More specifically, the invention relates to vectors comprising a nucleic acid encoding protein a56 or a fragment thereof and uses thereof. Furthermore, the present invention relates to antibodies that bind protein a56 or fragments thereof and uses thereof. The present invention uses an oncolytic virus as a vector comprising a nucleic acid encoding protein a56, or a fragment or mutant thereof, of the present invention, and thus when administered to an individual, primarily specifically kills only cancer cells. Furthermore, cancer cells that survive even after infection with oncolytic viruses express protein a56 on the cell surface, which enables them to be targeted for secondary anti-cancer therapy. Thus, according to one embodiment of the present invention, when a vector containing a nucleic acid encoding protein a56 or a fragment thereof, and an antibody that binds to a56 are used, cancer can be effectively treated.
Patients receive a conventional dressing made with gauze, cotton padding and inelastic bandage after the surgery. They are instructed to start light wrist movements on the first postoperative day and progress as tolerated, beginning rehabilitation with physiotherapy after 2 weeks postoperatively.
Cold stress negatively affects the welfare of calves in outdoor hutches. No studies have examined the potential benefits of pair housing calves to buffer against cold stress. Our study evaluated the effects of pair versus individual housing on thermoregulatory, behavioral, and growth performance responses of calves in outdoor hutches during a Wisconsin continental winter. Forty-eight Holstein-Friesian heifer calves were enrolled into 1 of 2 housing treatments: individually (n = 16 calves) or pair housed (n = 16 pairs; 32 calves). Calves were fed milk twice daily, with ad libitum access to starter and water. Step-down weaning began on d 42 of life, and all milk was removed on d 54. Data collection continued through d 59. Calves were restricted inside a hutch (pair-housed calves in the same hutch) for 1 h during wk 4, 6, and 9 of life; internal hutch air temperature (T) was recorded with data loggers, and rectal temperature (RT) was recorded outside the hutch before and after restriction. On the subsequent 3 d in those weeks, calves' locations (outside or inside a hutch) were recorded at 15-min intervals using time-lapse cameras. Linear mixed models (change in T and RT after 1 h) and generalized linear mixed models with a β distribution (proportion of time spent inside hutches) were used to evaluate the fixed effects of housing treatment, week of life, and their interaction. For pair-housed calves, preference to be together was evaluated using one-sample t-tests comparing the proportion of time they were observed in the same location against 50% (chance, no preference), separately for each week of life. Predicted dry matter intake (DMI) of starter and body weight (BW) were standardized by day of life using regression models and used to calculate average daily gain (ADG) and feed conversion ratio (FCR; DMI of starter/ADG). Linear mixed models were constructed for each measure, separately for the preweaning, weaning, and postweaning periods, with a fixed effect of housing treatment; the models for BW included birth weight as a covariate. All mixed models included a random term for housing unit (individual or pair of calves) nested within treatment. Hutch T increased more after 1 h with pair-housed calves inside than with those housed individually (+2.3 vs. 1.4°C, respectively; standard error of the mean = 0.26°C). However, no treatment differences were detected in RT. Individually housed calves spent more time inside the hutches than pair-housed ones (93.9 vs. 90.7% of total time, respectively; standard error of the mean = 0.8%), and the latter chose to be together most of the time, regardless of location (90.0 ± 1.3%, 88.6 ± 1.2%, and 79.4 ± 4.2% in wk 4, 6, and 9 of life, respectively). After weaning, there was some evidence suggesting that pair-housed calves had greater starter DMI than those housed individually. No effects of housing type were found on FCR, BW, or ADG. Our study is the first to explicitly examine the potential benefits of pair housing for alleviating cold stress in outdoor-housed dairy calves, and we found limited evidence in support of our hypotheses.
A topical liquid aerosol formulation for accurate metered dose delivery has been developed which includes a concentrate comprising a local anesthetic in a non-alcohol solvent and a hydrofluorocarbon (HFC) propellant. In the preferred embodiment, the concentration of the non-alcohol solvent in the concentrate is between about 75% and 85% by weight of the formulation. In the most preferred embodiment, the non-alcohol solvent is a water-soluble polyol such as ethylene glycol, propylene glycol, glycerol, diethylene glycol, dipropylene glycol, oligoalkylene glycols, liquid polyalkylene glycols, or combinations thereof. In one embodiment, the concentration of the local anesthetic in the concentrate is between about 15% and 25% by weight. In the preferred embodiment, the hydrofluorocarbon propellant is 1,1,1,2-tetrafluoroethane 1,1,1,2,3,3,3-heptafluoropropane or combinations thereof, in a concentration between about 35% and 65% by weight of the final formulation, more preferably between about 45% and 55% by weight of the final formulation. A particularly preferred formulation includes benzocaine, tetracaine, and butylaminobenzoate, wherein the concentration of benzocaine in the concentrate is 14% by weight, the concentration of tetracaine in the concentrate is 2% by weight, and the concentration of butylaminobenzoate in the concentrate is 2% by weight. It has been found that the formulation is more stable in the substantial absence of oxygen. The formulation is preferably administered using a metered dose device for release of a controlled amount of the local anesthetic.
Rehabilitation Program: The program was developed to target the deficits described in individuals with SPS. It included movement training, manual therapy, strengthening and stretching exercises, and patient education. Each supervised session lasted around 30 minutes, with 75% of the session for movement training. Three treating physiotherapists supervised the program and initially attended a training session to standardize the program.
Subjects, male or female, 18 years of age or older, received up to 24 doses of GSK2132231A intramuscularly in 4 cycles. In Cycle 1 (ending Week 13) 6 doses were administered at 2-week intervals; in Cycle 2 (ending Week 32) 6 doses at 3-week intervals; in Cycle 3 (ending Week 54) 4 doses at 6-week intervals and in Cycle 4 4 doses at 12-week intervals, starting 12 weeks after end of Cycle 3, followed by, after an interruption of treatment of 6 months, 4 doses at 24-week intervals.
A randomized trial compared prednisone plus IV melphalan to prednisone plus oral melphalan in the treatment of myeloma. As discussed below, overall response rates at week 22 were comparable; however, because of changes in trial design, conclusions as to the relative activity of the 2 formulations after week 22 are impossible to make. 

Both arms received oral prednisone starting at 0.8 mg/kg/day with doses tapered over 6 weeks. Melphalan doses in each arm were: Arm 1: Oral melphalan 0.15 mg/kg/day x 7 followed by 0.05 mg/kg/day when WBC began to rise. Arm 2: IV melphalan 16 mg/m2 q 2 weeks x 4 (over 6 weeks) followed by the same dose every 4 weeks. Doses of melphalan were adjusted according to the following criteria: 

Table 1. Criteria for Dosage Adjustment in a Randomized Clinical Trial

One hundred seven patients were randomized to the oral melphalan arm and 203 patients to the IV melphalan arm. More patients had a poor-risk classification (58% versus 44%) and high tumor load (51% versus 34%) on the oral compared to the IV arm (P<0.04). Response rates at week 22 are shown in the following table:

Table 2. Response Rates at Week 22

Because of changes in protocol design after week 22, other efficacy parameters such as response duration and survival cannot be compared. 

Severe myelotoxicity (WBC ≤1,000 and/or platelets ≤25,000) was more common in the IV melphalan arm (28%) than in the oral melphalan arm (11%). 

An association was noted between poor renal function and myelosuppression; consequently, an amendment to the protocol required a 50% reduction in IV melphalan dose if the BUN was ≥30 mg/dL. The rate of severe leukopenia in the IV arm in the patients with BUN over 30 mg/dL decreased from 50% (8/16) before protocol amendment to 11% (3/28) (P = 0.01) after the amendment. 

Before the dosing amendment, there was a 10% (8/77) incidence of drug-related death in the IV arm. After the dosing amendment, this incidence was 3% (3/108). This compares to an overall 1% (1/100) incidence of drug-related death in the oral arm.
The patients in the study arm will be converted from immediate release Tacrolimus to Envarsus. After obtaining informed consent, participants will undergo baseline tests for cognitive function and cerebral blood flow. After 12 weeks, cognition and brain blood flow will be assesses again in all enrolled patients.
Systems and methods are provided for monitoring medication compliance to allow a doctor or medical care provider to determine whether a subject is ingesting a prescribed medication at the proper times. This can include the capability of remote access to remotely monitor compliance. A medication container includes a plurality of medication-containing cells, with frangible covers overlaying each cell. An electrical circuit includes a sequential value element associated with each cell, with the sequential value elements being connected in parallel and having a unique value. When the cover of a cell is broken, the associated sequential value element is uncoupled from the electrical circuit. A measurement device calculates the combined value of the sequential value elements coupled to the electrical circuit to determine which of the cells have been accessed via breakage of the associated cover.
The invention discloses an oral combination of Chinese medicine used for treating gastric ulcer, which belongs to a field of traditional Chinese medicine. The medicine used for curing lower extremityvaricose vein is made by certain weight of rehmannia root, coix seed, medicinal cyathula root, Chinese corktree, unpeeled root of herbaceous peony, moutan bark, peach seed, safflower and Chinese stractylodes. Putting the material medicine into a marmite and adding water for proper soaking: first, using furious fire to boil, then using small fire to heat for half an hour. The liquid medicine is filtered, and proper water is added into the decoction medicine and heated for half an hour, and then the medicine liquid is filtered again.By adopting the formulation, the invention has the following clinical effects: 1. symptom can be effectively relieved with a highly total effective rate of 98.33 percent. 2. clinical symptom can be effectively improved and survival quality can be improved for patients: after taking the medicine for a month, pain is obviously decreased and blood circulation is improved for the ordinary patients.After taking the medicine for 2 months, venous thrombosis is gradually disintegrated and venous blood return is accelerated; after taking the medicine for 3 months, symptoms of swelling, pain, weakness of the lower limbs, numbness and coolness are essentially disappeared; black purple and indurative skin is tended to be normal. 3. the medicine is pure traditional Chinese medicinal preparation without adverse reaction.
Data have demonstrated that critically ill patients with septic shock who develop atrial fibrillation suffer a greater likelihood of death and other complications when compared with patients who remain in sinus rhythm, however, little evidence exists to inform treatment strategies in this population. Ours is a pilot study evaluating rhythm vs rate control strategies in patients with septic shock and respiratory failure requiring invasive mechanical ventilation who develop new onset atrial fibrillation (NOAF). Design will be prospective, randomized, open-label. Patients in the rhythm control arm will receive IV amiodarone infusion followed by attempt at electrical cardioversion within 24 hours development of NOAF. Those in the rate control arm will receive negative chronotropic agents (beta blockers, calcium channel blockers, amiodarone, or digoxin) at the discretion of the treating physician. Available patient data will be collected for a total of 180 days following enrollment, and outcomes assessed will include ICU length of stay, ventilator free days, and time on vasopressors
Hedrin Once Liquid Gel is a certified medical product for the removal of head lice and nits. The liquid gel contains 4% dimethicone and nerolidol (Penetrol®).
QSYMIA can cause cognitive dysfunction (e.g., impairment of concentration/attention, difficulty with memory, and speech or language problems, particularly word-finding difficulties). Rapid titration or high initial doses of QSYMIA may be associated with higher rates of cognitive events such as attention, memory, and language/word-finding difficulties [see Adverse Reactions (6.1)] . The concomitant use of alcohol or central nervous system (CNS) depressant drugs with QSYMIA may potentiate CNS depression or other centrally mediated effects of these agents, such as dizziness, cognitive adverse reactions, drowsiness, light-headedness, impaired coordination, and somnolence. 

Caution patients about operating hazardous machinery, including automobiles, until they are reasonably certain QSYMIA therapy does not affect them adversely. Caution patients against excessive alcohol intake while receiving QSYMIA.

If cognitive dysfunction persists, consider dosage reduction or discontinuation of QSYMIA [see Warnings and Precautions (5.9)] .
Participants were called every week for the first 8 weeks using a combination of TIP-C and SMH. The counselor called to assess and discuss interpersonal relationships, communication, social support, managing symptoms and survivorship. At the end of 8 weeks, the final 4 calls followed the SMSH alone protocol. At week 13, the second assessment was conducted.
PURPOSE: A composition containing extract of Pueraria lobata (Willd.) Ohwi, Rhynchosia Nulubilis, Pleuropterus multflorus, and Ponciri Fructus is provided to suppress 5alpha-reductase and to promote hair growth. CONSTITUTION: A composition for preventing hair loss and promoting hair growth contains extract of Pueraria lobata (Willd.) Ohwi, Rhynchosia Nulubilis, Pleuropterus multflorus, and Ponciri Fructus in a content of 1-10:1-10:1-10:1-10. The composition is used in the form of powder, liquid phase, or pill. The composition is hot water extract. The composition is obtained by adding 20-120g of Pueraria lobata (Willd.) Ohwi, Rhynchosia Nulubilis, Pleuropterus multflorus, and Ponciri Fructus per 1L of water, and extracting. The dose of active ingredient is 0.001mg/kg/day-2000mg/kg/day.
BACKGROUND: Musculoskeletal injuries are noticeably high among the nursing fraternity, with lower back pain (LBP) being the most prevalent. Therefore, this study aimed to map evidence on the burden of occupational musculoskeletal disorders (MSD) among nurses in sub-Saharan Africa (SSA).
METHODS: This scoping review was guided by Arksey and O'Malley's framework. We conducted a comprehensive literature search with no date limit from the following databases: Science Direct, PubMed, Sabinet (SA ePublications), EBSCOhost platform, World Health Organization (WHO) Library, Google Scholar, SCOPUS, Taylor and Francis, and WorldCat Academic Search with full text for published studies. The search took place from May 2022 to December 2022. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was used for reporting the search results, and a thematic content analysis was used to present the emerging themes from the included studies.
RESULTS: A total of 16,714 studies were identified after the database search. Only 29 studies met the inclusion criteria after full-article screening and were included for data extraction. The studies reported a total of 6343 participants from different regions in SSA. The 29 included studies showed evidence on the prevalence of MSD, associated risk factors of MSD and LBP among nurses in SSA with some recommendations on how to reduce the prevalence of MSD among nurses.
CONCLUSION: The study findings reveal that there is a high prevalence of MSD among nurses, especially LBP. The etiology of MSD among nurses is multifactorial, and multifaceted strategies to address MSD are recommended. Further research is recommended to explore strategies that can be used to curb the high prevalence of MSD among nurses.
<P>PROBLEM TO BE SOLVED: To provide compositions and methods for treating or preventing antibody mediated graft rejection.  <P>SOLUTION: The invention is based in part on the discovery that blood group epitopes can be specifically expressed at high density and by different core sugar chains on mucin-type protein backbones. The polypeptides are referred to herein as ABO fusion polypeptides. In one aspect, the invention provides a fusion polypeptide that includes a first polypeptide, comprising at least a region of a mucin polypeptide, and glycosylated by an α1,2 fucosyltransferase operably linked to a second polypeptide. The first polypeptide is sequentially glycosylated by an α1,3 N-acetylgalactosaminyl transferase and/or an α1,3 galactosyltransferase. The mucin polypeptide is for example PSGL-1.  <P>COPYRIGHT: (C)2009,JPO&INPIT
A pharmaceutical composition including an adjuvant effective amount of a protected inosine monophosphate (IMP) compound. The pharmaceutical composition includes the protected IMP compound alone, or in combination with vaccine agents with or without additional adjuvants. The pharmaceutical composition can be utilized as a vaccine composition or can be included with existing vaccine compositions in order to increase a specific T lymphocyte mediated immune response thereto. Various methods relating to the pharmaceutical composition and N the vaccine are described herein. The vaccines can be employed to prevent or treat infections. Additionally, the pharmaceutical compositions not only increase T-cell responses, but also confer, by pretreatment, non-specific protection against a variety of pathogens. This combination of actions is appropriate for enhancing defense against bioterrorism with organisms like smallpox or anthrax.